BenevolentAI Investor Presentation Deck
Al-enabled, hypothesis-driven drug discovery platform
Built for scientists, with scientists
Knowledge
Precision
Medicine
OB
EO
EO
The Benevolent Platform™
The Benevolent Platform™
continuously learns and improves
predictions
Iterative Learning
Further enhancing target identification &
accelerating end-to-end drug discovery
W
Predictive
Algorithms
Inferences
De Novo
molecular
design
0=
Target
Identification
Molecular
Design
Benevolent
Target
Triage
Experimental
validation
Comprehensive, mechanistic approach
to understand complex diseases
Identifying targets by understanding underlying disease drivers,
drawing on a multi-modal knowledge base
85+
data sources used
HAAP
X
Sophisticated Target Identification process
Commercially & scientifically validated disease agnostic
The Benevolent PlatformTM has generated all internal pipeline programmes &
supports multiple commercial partnerships
20+ internal programmes - Target discovery
to clinical with BEN2293 in P2 and second asset in IND
enabling studies
CKD, IPF, Heart Failure, SLE
Novel targets selected by AstraZeneca as part of
successful collaboration
COVID-19
Al-driven drug repurposing hypothesis led to FDA
emergency use approval of a Covid-19 drug licensed
to Eli Lilly by Incyte
Benevolent
AstraZeneca
LillyView entire presentation